CA2504042A1 - Procedes, substances et materiel permettant d'examiner des voies associees a la progression de glioblastome - Google Patents

Procedes, substances et materiel permettant d'examiner des voies associees a la progression de glioblastome Download PDF

Info

Publication number
CA2504042A1
CA2504042A1 CA002504042A CA2504042A CA2504042A1 CA 2504042 A1 CA2504042 A1 CA 2504042A1 CA 002504042 A CA002504042 A CA 002504042A CA 2504042 A CA2504042 A CA 2504042A CA 2504042 A1 CA2504042 A1 CA 2504042A1
Authority
CA
Canada
Prior art keywords
leu
ser
lys
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002504042A
Other languages
English (en)
Inventor
Paul S. Mischel
Charles L. Sawyers
Bradley L. Smith
Katherine Crosby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Cell Signaling Technology Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2504042A1 publication Critical patent/CA2504042A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Abstract

L'invention concerne des procédés d'examen et/ou d'évaluation quantitative de voies biochimiques qui sont déréglées dans des états pathologiques tels que le cancer. L'invention concerne également des agents réactifs et des trousses conçus pour effectuer ces procédés.
CA002504042A 2002-11-05 2003-11-05 Procedes, substances et materiel permettant d'examiner des voies associees a la progression de glioblastome Abandoned CA2504042A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42377702P 2002-11-05 2002-11-05
US60/423,777 2002-11-05
PCT/US2003/035115 WO2004044218A2 (fr) 2002-11-05 2003-11-05 Procedes, substances et materiel permettant d'examiner des voies associees a la progression de glioblastome

Publications (1)

Publication Number Publication Date
CA2504042A1 true CA2504042A1 (fr) 2004-05-27

Family

ID=32312710

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002504042A Abandoned CA2504042A1 (fr) 2002-11-05 2003-11-05 Procedes, substances et materiel permettant d'examiner des voies associees a la progression de glioblastome

Country Status (8)

Country Link
US (1) US20040106141A1 (fr)
EP (1) EP1567860A4 (fr)
JP (2) JP2006505793A (fr)
AU (1) AU2003291736A1 (fr)
CA (1) CA2504042A1 (fr)
DE (1) DE03768629T1 (fr)
ES (1) ES2245619T1 (fr)
WO (1) WO2004044218A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11821043B2 (en) 2017-08-17 2023-11-21 Nantomics Llc Dynamic changes in circulating free RNA of neural tumors

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006052249A1 (fr) * 2004-11-08 2006-05-18 The Regents Of The University Of California Procedes impliquant la voie de signalisation pi3k/akt dans des gliomes et des cancers de la prostate
WO2005007687A1 (fr) * 2003-07-09 2005-01-27 Dana-Farber Cancer Institute, Inc Compositions et procedes de modulation du declenchement folliculaire ovarien
BRPI0418022A (pt) * 2003-12-22 2007-04-17 Novartis Ag biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor
US8017321B2 (en) * 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
US20080113874A1 (en) * 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
ES2537631T3 (es) * 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
AU2006203884B2 (en) * 2005-01-06 2012-02-16 Genentech, Inc. Cancer prognostic, diagnostic and treatment methods
WO2006083936A2 (fr) 2005-01-31 2006-08-10 Genentech, Inc. Anticorps anti-ephb2 et methodes d'utilisation associees
AU2006223086A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
EP1899463A4 (fr) * 2005-05-09 2009-11-25 Ariad Pharma Inc Biomarqueurs permettant d'évaluer la probabilité selon laquelle une tumeur est sensible à un inhibiteur de mtor
US7713960B2 (en) * 2005-07-22 2010-05-11 University Of South Florida Inhibition of the Raf/Mek/P-Erk pathway for treating cancer
JP2009506303A (ja) * 2005-08-03 2009-02-12 ベンタナ・メデイカル・システムズ・インコーポレーテツド 癌の化学療法のための予測方法
AU2012200691B2 (en) * 2006-02-16 2013-07-04 Ventana Medical Systems, Inc. Reagents and methods for cancer prognosis and pathological staging
JP5143026B2 (ja) * 2006-02-16 2013-02-13 ベンタナ・メデイカル・システムズ・インコーポレーテツド 癌の予後診断及び病理学的病期分類のための試薬及び方法。
WO2007106432A2 (fr) * 2006-03-10 2007-09-20 George Mason Intellectual Properties, Inc. Statut du recepteur de l'egf pour le traitement des maladies
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
EP2032982B1 (fr) * 2006-05-05 2012-08-29 Yale University Utilisation de profils de localisation subcellulaires comme indicateurs de pronostic ou indicateurs de prévision
JP4795203B2 (ja) * 2006-11-13 2011-10-19 シスメックス株式会社 アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
BRPI0813583A2 (pt) * 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
CN101854804B (zh) * 2007-10-01 2014-07-23 利克斯特生物技术公司 Hdac抑制剂
WO2009126543A1 (fr) 2008-04-08 2009-10-15 Nuclea Biomarkers, Llc Panel de biomarqueurs pour la prédiction d'un cancer colorectal récurrent
AU2009277179A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (fr) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Procédés de modulation de la régulation cellulaire par inhibition de p53
US8058268B2 (en) * 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
EP2667195B1 (fr) * 2009-01-14 2016-12-14 The United States of America, as represented by The Secretary, Department of Health and Human Services Biomarqueurs basés sur des taux et méthodes d'utilisation associées
WO2011050351A2 (fr) * 2009-10-23 2011-04-28 The Translational Genomics Research Institute Procédés et trousses utilisés dans le cadre de l'identification du glioblastome
US8338456B2 (en) * 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
WO2012145426A1 (fr) * 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Procédés pour traiter un cancer utilisant la cyclosporine et des dérivés de cyclosporine
AU2012347522B2 (en) 2011-12-08 2015-07-30 Five3 Genomics, Llc MDM2-containing double minute chromosomes and methods therefore
CN105209036B (zh) 2013-04-09 2018-10-26 莱克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯的配制品
US10941194B2 (en) 2015-01-22 2021-03-09 The Regents Of The University Of California Methods of diagnosing and treating autism spectrum disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
US6020199A (en) * 1999-07-21 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of PTEN expression
WO2003081210A2 (fr) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification d'inhibiteurs de kinase
AU2003223495A1 (en) * 2002-04-05 2003-10-27 Cell Signaling Technology, Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11821043B2 (en) 2017-08-17 2023-11-21 Nantomics Llc Dynamic changes in circulating free RNA of neural tumors

Also Published As

Publication number Publication date
DE03768629T1 (de) 2006-01-26
AU2003291736A8 (en) 2004-06-03
US20040106141A1 (en) 2004-06-03
WO2004044218A2 (fr) 2004-05-27
JP2009115817A (ja) 2009-05-28
EP1567860A2 (fr) 2005-08-31
WO2004044218A3 (fr) 2004-12-02
AU2003291736A1 (en) 2004-06-03
JP2006505793A (ja) 2006-02-16
ES2245619T1 (es) 2006-01-16
EP1567860A4 (fr) 2006-05-10

Similar Documents

Publication Publication Date Title
US20040106141A1 (en) Methods and materials for examining pathways associated with glioblastoma progression
US10273308B2 (en) Methods of producing antibodies specific for p95
Laurent-Puig et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
Eberhard et al. Biomarkers of response to epidermal growth factor receptor inhibitors in non–small-cell lung cancer working group: standardization for use in the clinical trial setting
Carey et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-β pathway signaling indicates response to primary chemotherapy
Ross et al. HER-2/neu testing in breast cancer
Nagy et al. Expression of VEGF, VEGFR, EGFR, COX-2 and MVD in cervical carcinoma, in relation with the response to radio-chemotherapy
WO2006116016A2 (fr) Determinants moleculaires de la reponse de l'inhibiteur d'egfr kinase dans le glioblastome
Dimou et al. Measurement of aldehyde dehydrogenase 1 expression defines a group with better prognosis in patients with non-small cell lung cancer
Schindlbeck et al. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIα, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow
Dahl et al. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer
Powell et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility
JP5893037B2 (ja) Ｂｒａｆｖ６００ｅに特異的に結合する抗体を使用する癌の診断のための手段及び方法
Olmez et al. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme
Murakawa et al. Expression of KIT, EGFR, HER‐2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach
Yeh Measuring HER-2 in breast cancer: immunohistochemistry, FISH, or ELISA?
Da Silva et al. Pilot assessment of vascular endothelial growth factor receptors and trafficking pathways in recurrent and metastatic canine subcutaneous mast cell tumours
US20130072397A1 (en) Methods for the diagnosis and prognosis of a tumor using bcat1 protein
EP2005186A2 (fr) Expression ercc1 dans la prédiction de la réponse à une chimiothérapie du cancer
Becker et al. Extraction of phosphorylated proteins from formalin-fixed cancer cells and tissues
WO2006052249A1 (fr) Procedes impliquant la voie de signalisation pi3k/akt dans des gliomes et des cancers de la prostate
Abu Al Karsaneh et al. Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients
US20080299589A1 (en) Methods and Materials for Examining the P13k/Akt Pathway in Gliomas and Prostate Cancers
US20120134995A1 (en) Method for predicting the therapeutic responseiveness of a patient to a medical treatment with an egfr inhibitor
Liang et al. Study on the SPARC Expression and Relationship with Survival in Colorectal Cancer Patients in Han, Buyi and Miao Race

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued